Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

NovoCodex Starts China Trial of anti-CD70 ADC in Solid Tumors

publication date: Nov 9, 2022

Shanghai NovoCodex Biopharm started a China Phase 1 trial of an anti-CD70 ADC in patients with advanced solid tumors. NovoCodex, a majority owned subsidiary of Zhejiang Medicine, acquired China rights to the candidate, ARX305, from San Diego’s Ambrx in 2019, its second in-licensing from the company. According to Ambrx, ARX305 is the only anti-CD70 ADC in active development that targets CD70, a protein overexpressed in a broad range of solid and hematologic tumors. More details....

Stock Symbols: (SHA: 600216) (NYSE: AMAM)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here

BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here

Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here